Indeed, tumor-specific TBL1 inactivation was sufficient to either reverse disease burden of established tumors or even prevent tumor development at an earlier stage, correlating with enhanced tumor susceptibility to chemotherapeutic intervention. This evidence concerns the gene TBL1Y and neoplasm.